Please wait a minute...
文章检索
预防医学  2025, Vol. 37 Issue (6): 603-607    DOI: 10.19485/j.cnki.issn2096-5087.2025.06.013
  疾病控制 本期目录 | 过刊浏览 | 高级检索 |
2014—2023年余姚市原发性肝癌死亡与疾病负担分析
董沙沙, 项云飞
余姚市疾病预防控制中心,浙江 余姚 315400
Mortality and disease burden of primary liver cancer in Yuyao City from 2014 to 2023
DONG Shasha, XIANG Yunfei
Yuyao Center for Disease Control and Prevention, Yuyao, Zhejiang 315400, China
全文: PDF(920 KB)  
输出: BibTeX | EndNote (RIS)      
摘要 目的 了解2014—2023年浙江省余姚市原发性肝癌(PLC)死亡和疾病负担变化趋势,为制定综合性PLC防治策略提供参考。方法 通过宁波市慢性病监测系统收集2014—2023年余姚市户籍居民PLC死亡资料,计算粗死亡率;采用2010年第六次全国人口普查数据计算中国人口标化死亡率(中标死亡率),采用Segi's 1960世界标准人口构成计算世界人口标化死亡率(世标死亡率),分析不同性别、年龄人群PLC死亡特征;采用潜在减寿年数(PYLL)、平均减寿年数(AYLL)和潜在减寿率(PYLLR)分析PLC疾病负担;采用平均年度变化百分比(AAPC)分析2014—2023年PLC死亡率和疾病负担变化趋势。结果 2014—2023年余姚市PLC死亡2 072例,粗死亡率为24.81/10万,中标死亡率为14.24/10万,世标死亡率为10.85/10万,呈下降趋势(AAPC=-5.874%、-9.053%和-9.147%,均P<0.05)。男性PLC粗死亡率为35.93/10万,高于女性的14.02/10万(P<0.05);男性、女性PLC粗死亡率、中标死亡率和世标死亡率变化趋势和全人群一致。PLC死亡年龄最小9.42岁,最大96.91岁,平均死亡年龄由2014年的64.34岁增至2023年的69.81岁(AAPC=0.965%,P<0.05)。PLC粗死亡率随年龄增长呈上升趋势(P<0.05),≥85岁组达峰值,为94.61/10万。PLC PYLL为17 018.00人年,AYLL为13.60年/人,PYLLR为2.89‰;2014—2023年PYLL、PYLLR呈下降趋势(AAPC=-10.543%、-9.789%,均P<0.05)。结论 2014—2023年余姚市PLC死亡率、PYLL和PYLLR均呈下降趋势,男性和老年人是PLC防治重点人群。
服务
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章
董沙沙
项云飞
关键词 原发性肝癌死亡率潜在减寿年数平均年度变化百分比    
AbstractObjective To understand the trend of mortality and life loss of primary liver cancer (PLC) in Yuyao City from 2014 to 2023, so as to provide the basis for formulating comprehensive prevention and treatment strategies of PLC. Methods The PLC mortality data of registered population in Yuyao City from 2014 to 2023 were collected from Ningbo Municipal Chronic Disease Surveillance System. Crude mortality of PLC was calculated, and standardized using the data from the Sixth National Population Census in 2010 (Chinese-standardized rate) and the Segi's world standard population in 1960 (world-standardized rate). The mortality characteristics of PLC among different genders and age groups were analyzed. The disease burden of PLC was assessed using potential years of life lost (PYLL), average years of life lost (AYLL), and potential years of life lost rate (PYLLR). The trends in PLC mortality and disease burden from 2014 to 2023 were analyzed using the average annual percent change (AAPC). Results There were 2 072 PLC deaths in Yuyao City from 2014 to 2023, and the crude mortality was 24.81/105, the Chinese-standardized rate was 14.24/105, and world-standardized rate was 10.85/105, all showed a downward trend (AAPC=-5.874%, -9.053% and -9.147%, all P<0.05). The crude mortality in males was higher than that in female (35.93/105 vs. 14.02/105, P<0.05). The trends in crude mortality, Chinese-standardized rate, and world-standardized rate of PLC for males and females were consistent with those of the entire population. The youngest age at death from PLC was 9.42 years, and the oldest was 96.91 years. The average age at death increased from 64.34 years in 2014 to 69.81 years in 2023 (AAPC=0.965%, P<0.05). The crude mortality rate of PLC increased with age (P<0.05), reaching a peak at 94.61/105 in those aged ≥85 years. The PYLL of PLC was 17 018.00 person-years, the AYLL was 13.60 years/person, and the PYLLR was 2.89‰. From 2014 to 2023, both PYLL and PYLLR showed downward trends (AAPC=-10.543% and -9.789%, both P<0.05). Conclusions From 2014 to 2023, the mortality, PYLL, and PYLLR of PLC in Yuyao City all showed downward trends. Men and the elderly were key groups for the prevention and control of PLC.
Key wordsprimary liver cancer    mortality    potential years of life loss    average annual percent change
收稿日期: 2025-03-04      修回日期: 2025-05-15      出版日期: 2025-06-10
中图分类号:  R735.7  
作者简介: 董沙沙,本科,医师,主要从事慢性病预防控制工作
通信作者: 项云飞,E-mail:260832850@qq.com   
引用本文:   
董沙沙, 项云飞. 2014—2023年余姚市原发性肝癌死亡与疾病负担分析[J]. 预防医学, 2025, 37(6): 603-607.
DONG Shasha, XIANG Yunfei. Mortality and disease burden of primary liver cancer in Yuyao City from 2014 to 2023. Preventive Medicine, 2025, 37(6): 603-607.
链接本文:  
http://www.zjyfyxzz.com/CN/10.19485/j.cnki.issn2096-5087.2025.06.013      或      http://www.zjyfyxzz.com/CN/Y2025/V37/I6/603
[1] BRAY F,LAVERSANNE M,SUNG H,et al.Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2024,74(3):229-263.
[2] 郑荣寿,陈茹,韩冰峰,等.2022年中国恶性肿瘤流行情况分析[J].中华肿瘤杂志,2024,46(3):221-231.
ZHENG R S,CHEN R,HAN B F,et al.Cancer incidence and mortality in China,2022[J].Chin J Oncol,2024,46(3):221-231.(in Chinese)
[3] 应焱燕,王永,陈洁平,等.2002—2021年宁波市肝癌死亡趋势分析[J].预防医学,2022,34(12):1218-1223.
YING Y Y,WANG Y,CHEN J P,et al.Trend in mortality of liver cancer in Ningbo City from 2002 to 2021[J].China Prev Med J,2022,34(12):1218-1223.(in Chinese)
[4] 胡碧波,傅克本,顾永权.2011—2018年余姚市恶性肿瘤发病趋势[J].预防医学,2023,35(1):44-47,52.
HU B B,FU K B,GU Y Q,et al.Trends in incidence of malignant tumors in Yuyao City from 2011 to 2018[J].China Prev Med J,2023,35(1):44-47,52.(in Chinese)
[5] 柴文杰,王良友,乔冬菊,等.2010—2016年台州市居民肝癌发病和死亡趋势分析[J].预防医学,2019,31(9):933-935,939.
CHAI W J,WANG L Y,QIAO D J,et al.Tendency analysis of incidence and mortality of hepatocellular carcinoma in Taizhou residents from 2010 to 2016[J].China Prev Med J,2019,31(9):933-935,939.(in Chinese)
[6] 沈飞琼,杨金华,李其龙,等.2010—2014年浙江省肿瘤登记地区肝癌发病与死亡分析[J].中国肿瘤,2019,28(10):764-768.
SHEN F Q,YANG J H,LI Q L,et al.Incidence and mortality of liver cancer in Zhejiang cancer registration areas from 2010 to 2014[J].China Cancer,2019,28(10):764-768.(in Chinese)
[7] 林菲,王倩,朱晓云.2002—2018年上海市金山区主要消化系统恶性肿瘤发病和死亡趋势分析[J].中国肿瘤,2023,32(10):760-765.
LIN F,WANG Q,ZHU X Y.Incidence and mortality trends of major digestive system cancers in Jinshan district of Shanghai from 2002 to 2018[J].China Cancer,2023,32(10):760-765.(in Chinese)
[8] WANG M J,WANG Y T,FENG X S,et al.Contribution of hepatitis B virus and hepatitis C virus to liver cancer in China north areas: experience of the Chinese National Cancer Center[J].Int J Infect Dis,2017,65:15-21.
[9] QU C F,CHEN T Y,FAN C S,et al.Efficacy of neonatal HBV vaccination on liver cancer and other liver diseases over 30-year follow up of the Qidong hepatitis B intervention study:a cluster randomized controlled trail[J/OL].PLoS Med,2014,11(12)[2025-05-15].https://doi.org/10.1371/journal.pmed.1001774.
[10] 丁贤彬,何大学,练雪梅,等.2012年至2020年重庆地区居民肝癌死亡率及疾病负担变化趋势[J].现代肿瘤医学,2023,31(6):1136-1140.
DING X B,HE D X,LIAN X M,et al.Trend of mortality and disease burden of liver cancer from 2012 to 2020 in Chongqing[J].Mod Oncol,2023,31(6):1136-1140.(in Chinese)
[11] 邓颖,王丹,成姝雯,等.2009—2019年四川省肝癌流行及生存情况分析[J].预防医学情报杂志,2023,39(4):359-363.
DENG Y,WANG D,CHENG S W,et al.Analysis of the prevalence and survival situation of liver cancer in Sichuan Province from 2009 to 2019[J].J Prev Med Inf,2023,39(4):359-363.(in Chinese)
[12] 周新凤,魏志梅,周成宇,等.顺德地区不同性别人群的肝癌影响因素分析[J].中华疾病控制杂志,2019,23(2):129-133.
ZHOU X F,WEI Z M,ZHOU C Y,et al.Analysis of influencing factors for liver cancer by gender in Shunde region[J].Chin J Dis Control Prev,2019,23(2):129-133.(in Chinese)
[13] GUAN X,ZHANG Q,XING J,et al.Systolic blood pressure mediates body mass index and non-alcoholic fatty liver disease:a population-based study[J].Turk J Gastroenterol,2021,32(5):458-465.
[14] 张敏,张裕晓,胡恒,等.1990—2019年中国归因于高体质量指数的肝癌死亡趋势及年龄-时期-队列分析[J].长治医学院学报,2023,37(3):171-176.
ZHANG M,ZHANG Y X,HU H,et al.Death trend and age-period-cohort analysis of liver cancer attributed to high BMI in China from 1990 to 2019[J].J Changzhi Medical Coll,2023,37(3):171-176.(in Chinese)
[15] 陈倩倩,芮法娟,倪文婧,等.原发性肝癌的流行病学及其危险因素研究进展[J].中国全科医学,2024,27(6):637-642.
CHEN Q Q,RUI F J,NI W J,et al.Research progress in epidemiology and risk factors of primary liver cancer[J].Chin Gen Pract,2024,27(6):637-642.(in Chinese)
[16] 朱银潮,许国章,张涛,等.浙江省宁波市市民健康相关行为现状[J].中国健康教育,2010,26(8):622-623,629.
ZHU Y C,XU G Z,ZHANG T,et al.Status of health related behaviors among residents in Ningbo Ctiy,Zhejiang Province[J].Chin J Health Educ,2010,26(8):622-623,629.(in Chinese)
[17] 陈亦晨,曲晓滨,孙良红,等.2002—2019年上海市浦东新区居民肝癌死亡特征及减寿率分析[J].中国全科医学,2021,24(12):1517-1522.
CHEN Y C,QU X B,SUN L H,et al.Liver carcinoma-related mortality and potential years of life lost among residents in Pudong New Area of Shanghai between 2002 and 2019[J].Chin Gen Pract,2021,24(12):1517-1522.(in Chinese)
[1] 朱颖, 郑添. 2013—2023年嘉善县居民期望寿命变化[J]. 预防医学, 2025, 37(6): 598-602.
[2] 丁哲渊, 杨研, 傅天颖, 鲁琴宝, 王心怡, 吴昊澄, 刘魁, 林君芬, 吴晨. 2024年浙江省法定传染病疫情分析[J]. 预防医学, 2025, 37(5): 433-438,442.
[3] 任露露, 顾嘉昌, 闵艺璇, 张思晨, 乔健健, 肖月, 胡静. 2016—2023年宜兴市脑卒中发病趋势分析[J]. 预防医学, 2025, 37(5): 498-502.
[4] 李慧君, 叶振淼, 樊丽辉, 郑宇航, 谢轶敏, 姜雪霞, 高豪俊, 张默涵, 罗永园. 2015—2023年温州市老年人跌倒死亡趋势与减寿分析[J]. 预防医学, 2025, 37(5): 460-464.
[5] 王洪岩, 任飞林, 刘小琦, 金玫华, 吴振乾. 2009—2023年湖州市HIV/AIDS病例新发现率趋势分析[J]. 预防医学, 2025, 37(4): 395-399.
[6] 叶振淼, 樊丽辉, 姜雪霞, 郑宇航, 张默涵, 罗永园, 谢轶敏, 李慧君, 金茜. 2014—2023年温州市胃癌死亡及减寿趋势分析[J]. 预防医学, 2025, 37(3): 267-271.
[7] 沈敏, 郁智慧, 朱爱韬. 1992—2021年中国慢性阻塞性肺疾病发病和死亡的年龄-时期-队列分析[J]. 预防医学, 2025, 37(2): 113-117.
[8] 裘凤黔, 赵俊峰, 陈玮华, 杜娟, 纪云芳, 高淑娜, 蒙洁, 何丽华, 陈博, 张艳. 2002—2019年黄浦区肺癌发病和死亡趋势分析[J]. 预防医学, 2025, 37(2): 143-147.
[9] 温佳鑫, 蒋俊鹏, 冯敏, 沈晓晨, 李晓印. 1990—2021年中国类风湿关节炎疾病负担趋势分析[J]. 预防医学, 2025, 37(1): 26-30.
[10] 章群, 王永, 陈洁平, 包凯芳, 冯玥溢, 王小丽. 2011—2023年宁波市前列腺癌发病和死亡趋势分析[J]. 预防医学, 2025, 37(1): 46-50.
[11] 叶振淼, 樊丽辉, 郑宇航, 姜雪霞, 李慧君, 张默涵, 谢轶敏, 罗永园, 金茜. 温州市乳腺癌死亡及减寿分析[J]. 预防医学, 2024, 36(9): 746-749.
[12] 赵思远, 徐焱, 张秋. 2013—2023年姑苏区居民伤害死亡特征[J]. 预防医学, 2024, 36(6): 532-535.
[13] 傅天颖, 吴昊澄, 鲁琴宝, 丁哲渊, 王心怡, 杨珂, 吴晨, 林君芬. 2023年浙江省法定传染病疫情分析[J]. 预防医学, 2024, 36(5): 369-373.
[14] 叶振淼, 樊丽辉, 郑宇航, 张默涵, 姜雪霞, 罗永园, 谢轶敏, 金茜, 李慧君. 2014—2022年温州市肝癌死亡趋势分析[J]. 预防医学, 2024, 36(5): 393-396.
[15] 吴丹红, 王伟霞, 王良友, 乔冬菊, 黄依璐, 张嫣. 台州市4类慢性病死亡及早死概率分析[J]. 预防医学, 2024, 36(5): 428-431,436.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed